Healios K.K Management

Management criteria checks 2/4

Healios K.K's CEO is Hardy Kagimoto, appointed in Feb 2012, has a tenure of 12.83 years. directly owns 31.88% of the company’s shares, worth ¥4.88B. The average tenure of the management team and the board of directors is 8.8 years and 6.9 years respectively.

Key information

Hardy Kagimoto

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure12.8yrs
CEO ownership31.9%
Management average tenure8.8yrs
Board average tenure6.9yrs

Recent management updates

Recent updates

Is Healios K.K (TSE:4593) Weighed On By Its Debt Load?

Dec 05
Is Healios K.K (TSE:4593) Weighed On By Its Debt Load?

Is Healios K.K (TSE:4593) Using Too Much Debt?

May 31
Is Healios K.K (TSE:4593) Using Too Much Debt?

CEO

Hardy Kagimoto (48 yo)

12.8yrs

Tenure

Dr. Tadahisa S. Kagimoto, also known as Hardy, MD, serves as Chairman, Chief Executive Officer and President of Aqumen Biopharmaceuticals, K.K. He served as Director of Athersys, Inc. since June 18, 2018 u...


Leadership Team

NamePositionTenureCompensationOwnership
Tadahisa S. Kagimoto
Chairman & CEO12.8yrsno data31.88%
¥ 4.9b
Richard P. Kincaid
CFO, Executive Officer & Internal Director5.4yrsno data0.21%
¥ 31.9m
Kouichi Tamura
Executive Officerno datano datano data
Masanori Sawada
Executive VP & Chief Medical Officer9.8yrsno datano data
Yoshinari Matsuda
Managing Director8.8yrsno datano data
Hironobu Kimura
Head of the Research Division6.3yrsno datano data

8.8yrs

Average Tenure

48yo

Average Age

Experienced Management: 4593's management team is seasoned and experienced (8.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Tadahisa S. Kagimoto
Chairman & CEO12.8yrsno data31.88%
¥ 4.9b
Richard P. Kincaid
CFO, Executive Officer & Internal Director6.9yrsno data0.21%
¥ 31.9m
Glenn J. Gormley
Independent Outside Director2.9yrsno datano data
Seigo Kashii
Independent External Director6.9yrsno data0.00022%
¥ 33.7k
Hideki Takeda
Auditor7.9yrsno data0.56%
¥ 85.7m
Yuko Yogo
Independent Outside Director2.9yrsno datano data

6.9yrs

Average Tenure

66.5yo

Average Age

Experienced Board: 4593's board of directors are considered experienced (6.9 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 12:58
End of Day Share Price 2024/12/25 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Healios K.K. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hidemaru YamaguchiCitigroup Inc
Akinori UedaGoldman Sachs
Miyabi YamakitaJefferies LLC